Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release drug delivery platform technology. The company targets conditions requiring complex dosing regimens, with an initial emphasis on Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. Cingulate’s pipeline leverages its PTR platform to create once-daily, multi-dose tablets designed to improve patient compliance, reduce side effects, and address unmet medical needs in chronic therapeutic areas.
The company generates revenue through the development and potential commercialization of its drug candidates, primarily targeting the ADHD and anxiety markets. Its lead product, CTx-1301 (dexmethylphenidate), is under review by the U. S. Food and Drug Administration (FDA) for the treatment of ADHD in patients aged 6 and older, with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. Upon approval, Cingulate expects to commercialize CTx-1301 through partnerships with third-party service providers, including Indegene and IQVIA, which will handle marketing, sales, and distribution. Additional revenue streams may emerge from the development of CTx-1302 (dextroamphetamine) for ADHD and CTx-2103 (buspirone) for anxiety, as well as potential licensing agreements for its PTR platform technology.
The company operates through the following segments:
- ADHD Therapeutics: This segment focuses on the development and commercialization of stimulant-based treatments for ADHD, including CTx-1301 and CTx-1302. Both candidates are designed to provide immediate onset of action within 30 minutes, entire active-day efficacy, and a controlled descent of drug blood levels to minimize crash and rebound symptoms. CTx-1301, the most advanced candidate, has completed Phase 3 trials and is under FDA review, while CTx-1302 remains in the planning stages pending additional capital.
- Anxiety Therapeutics: This segment is centered on CTx-2103, a once-daily formulation of buspirone for the treatment of anxiety. CTx-2103 aims to address the limitations of current buspirone therapies, which require multiple daily doses due to the drug’s short half-life. The candidate has completed a human formulation study demonstrating its ability to deliver a triple-release profile, and the company plans to pursue approval under the 505(b)(2) regulatory pathway.
- Platform Technology: This segment encompasses the proprietary PTR drug delivery platform, which enables the development of precision-timed, multi-dose tablets. The platform is designed to improve patient outcomes by enhancing compliance and reducing the need for booster doses. Cingulate intends to leverage this technology to expand its pipeline into additional therapeutic areas, including insomnia, pain, Alzheimer’s, and depression, among others.
Cingulate operates in the highly competitive ADHD and anxiety treatment markets, where it faces established players such as Takeda, Novartis, and Janssen, as well as smaller biotechnology firms. The company’s competitive advantage lies in its PTR platform, which enables the creation of true once-daily therapies with improved efficacy and tolerability profiles. Unlike existing extended-release stimulants, which often require booster doses and fail to provide full-day coverage, Cingulate’s candidates are engineered to deliver precise, timed releases of active pharmaceutical ingredients. This differentiation positions the company to capture market share in a segment where patient compliance and side effect management remain significant challenges. Additionally, the FDA’s revised bioequivalence guidelines for generic methylphenidate products may limit future generic competition, further strengthening Cingulate’s market position.
The company’s customer base includes healthcare providers, such as psychiatrists and pediatricians, who prescribe ADHD and anxiety medications. Upon commercialization, Cingulate’s products will target patients across three segments: children aged 6 to 12, adolescents aged 13 to 17, and adults aged 18 and older. The company has partnered with Indegene and IQVIA to support commercialization efforts, including marketing, market access, and field sales, ensuring broad reach to physicians, payers, and patients. While specific customer names are not disclosed, the company’s focus on large, underserved patient populations in the U. S. positions it to serve a diverse and expanding market.